According to Theravance Biopharma
's latest financial reports the company has โน7.87 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | โน8.52 B | -68.53% |
2022-12-31 | โน27.09 B | 109.89% |
2021-12-31 | โน12.91 B | -39.73% |
2020-12-31 | โน21.42 B | 6.98% |
2019-12-31 | โน20.02 B | -43.32% |
2018-12-31 | โน35.33 B | 58.74% |
2017-12-31 | โน22.25 B | -34.64% |
2016-12-31 | โน34.05 B | 197.16% |
2015-12-31 | โน11.45 B | -28.99% |
2014-12-31 | โน16.13 B | |
2013-12-31 | N/A |